Age [years; median (IQR)]
|
52.00 (43.00–60.00)
|
51.00 (43.00–60.00)
|
52.50 (44.00–60.25)
|
0.683
|
Sex [cases (%)]
|
0.933
|
Male
|
379 (87.73)
|
285 (87.96)
|
94 (87.04)
| |
Female
|
53 (12.27)
|
39 (12.04)
|
14 (12.96)
| |
Hepatitis B surface antigen [cases (%)]
|
0.937
|
Present
|
369 (85.42)
|
276 (85.19)
|
93 (86.11)
| |
Absent
|
63 (14.58)
|
48 (14.81)
|
15 (13.89)
| |
Child–Pugh score [cases (%)]
|
0.931
|
5
|
359 (83.10)
|
268 (82.72)
|
91 (84.26)
| |
6
|
69 (15.97)
|
53 (16.36)
|
16 (14.81)
| |
7
|
4 (0.93)
|
3 (0.93)
|
1 (0.93)
| |
AFP [ng/mL; median (IQR)]
|
91.45 (6.39–1705.00)
|
93.89 (6.79–1573.50)
|
78.82 (5.00–2231.75)
|
0.482
|
CA19-9 [ng/mL; median (IQR)]
|
19.24 (10.44–33.99)
|
20.18 (11.05–34.42)
|
15.96 (8.58–30.32)
|
0.692
|
AST (IU/L; mean ± SD)
|
41.50 ± 33.02
|
41.88 ± 35.45
|
40.36 ± 24.43
|
0.680
|
ALT (IU/L; mean ± SD)
|
41.93 ± 34.14
|
43.25 ± 37.22
|
38.00 ± 22.18
|
0.167
|
Hemoglobin (g/L; mean ± SD)
|
154.56 ± 193.60
|
157.11 ± 223.40
|
146.93 ± 13.97
|
0.636
|
Albumin (g/dL; mean ± SD)
|
43.28 ± 3.34
|
43.22 ± 3.41
|
43.47 ± 3.11
|
0.498
|
Bilirubin (mg/dL; mean ± SD)
|
13.32 ± 4.94
|
13.31 ± 4.95
|
13.36 ± 4.96
|
0.916
|
Platelet count (× 103/mm3; mean ± SD)
|
185.62 ± 72.00
|
184.02 ± 67.22
|
190.45 ± 84.93
|
0.422
|
Prothrombin time (INR; mean ± SD)
|
1.01 ± 0.08
|
1.02 ± 0.08
|
1.01 ± 0.08
|
0.264
|
HBV-DNA copy number (Log; mean ± SD)
|
2.46 ± 2.41
|
2.54 ± 2.42
|
2.22 ± 2.38
|
0.233
|
Bleeding [mL; median (IQR)]
|
200 (100–400)
|
200.00 (100–400)
|
275.00 (100–500)
|
0.834
|
Hospital stay (days; mean ± SD)
|
11.64 ± 3.87
|
11.67 ± 3.83
|
11.55 ± 3.98
|
0.774
|
Operation time (min; mean ± SD)
|
157.32 ± 58.95
|
155.02 ± 57.54
|
164.23 ± 62.77
|
0.160
|
Portal vein embolization [cases (%)]
|
1.000
|
Yes
|
143 (33.10)
|
107 (33.02)
|
36 (33.33)
| |
No
|
289 (66.90)
|
217 (66.98)
|
72 (66.67)
| |
Tumor size [cm; median (IQR)]
|
5.00 (3.00–8.00)
|
5.00 (2.95–8.00)
|
4.00 (3.00–8.00)
|
0.932
|
Tumor location [cases (%)]a
|
0.066
|
Central
|
270 (62.5)
|
194 (59.9)
|
76 (70.4)
| |
Non-central
|
162 (37.5)
|
130 (40.1)
|
32 (29.6)
| |
Tumor lesions [cases (%)]
|
0.375
|
1
|
320 (74.07)
|
236 (72.84)
|
84 (77.78)
| |
2–3
|
112 (25.93)
|
88 (27.16)
|
24 (22.22)
| |
Liver macronodular cirrhosis [cases (%)]
|
0.248
|
None
|
111 (25.69)
|
87 (26.85)
|
24 (22.22)
| |
Light
|
304 (70.37)
|
226 (69.75)
|
78 (72.22)
| |
Medium
|
14 (3.24)
|
8 (2.47)
|
6 (5.56)
| |
Heavy
|
3 (0.69)
|
3 (0.93)
|
0 (0.00)
| |
Cancer cell differentiation [cases (%)]
|
0.811
|
Low
|
213 (49.31)
|
162 (50.00)
|
51 (47.22)
| |
Medium
|
205 (47.45)
|
151 (46.60)
|
54 (50.00)
| |
High
|
14 (3.24)
|
11 (3.40)
|
3 (2.78)
| |
Tumor thrombus [cases (%)]
|
0.546
|
Present
|
36 (8.33)
|
29 (8.95)
|
7 (6.48)
| |
Absent
|
396 (91.67)
|
295 (91.05)
|
101 (93.52)
| |
MVI [cases (%)]
|
0.336
|
Present
|
175 (40.51)
|
136 (41.98)
|
39 (36.11)
| |
Absent
|
257 (59.49)
|
188 (58.02)
|
69 (63.89)
| |
Surgical procedure [cases (%)]
|
0.608
|
Irregular
|
263 (60.88)
|
200 (61.73)
|
63 (58.33)
| |
Regular
|
169 (39.12)
|
124 (38.27)
|
45 (41.67)
| |
Tumor encapsulation [cases (%)]
|
0.586
|
No
|
153 (35.42)
|
119 (36.73)
|
34 (31.48)
| |
Incomplete
|
109 (25.23)
|
79 (24.38)
|
30 (27.78)
| |
Complete
|
170 (39.35)
|
126 (38.89)
|
44 (40.74)
| |
Tumor boundary [cases (%)]
|
0.546
|
Clear
|
396 (91.67)
|
295 (91.05)
|
101 (93.52)
| |
Unclear
|
36 (8.33)
|
29 (8.95)
|
7 (6.48)
| |
8th AJCC T stage [cases (%)]
|
0.320
|
T1a
|
66 (15.28)
|
44 (13.58)
|
22 (20.37)
| |
T1b
|
142 (32.87)
|
104 (32.10)
|
38 (35.19)
| |
T2
|
157 (36.34)
|
123 (37.96)
|
34 (31.48)
| |
T3
|
65 (15.05)
|
51 (15.74)
|
14 (12.96)
| |
T4
|
2 (0.46)
|
2 (0.62)
|
0 (0.00)
| |
BCLC stage [cases (%)]
|
0.731
|
0
|
31 (7.18)
|
23 (7.10)
|
8 (7.41)
| |
A1
|
289 (66.90)
|
213 (65.74)
|
76 (70.37)
| |
A2
|
18 (4.17)
|
15 (4.63)
|
3 (2.78)
| |
B
|
94 (21.76)
|
73 (22.53)
|
21 (19.44)
| |
Follow-up time [months; median (IQR)]
|
14.38 (4.60–29.38)
|
13.58 (4.49–26.41)
|
23.10 (6.63–32.79)
|
0.012
|